

Effect of COVID-19 in Cancer Patients

Adarsh Singharoy, Komal Muneshwar^{*}

Department of Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Wardha, Maharashtra, India

ABSTRACT

The evidential studies would indicate that there are a large number of people with cancer or cancer survivors who would have an on-going COVID infection or may have got a COVID infection sometime in their lives. The analytical study done with all stages and types of neoplasm with data collected in the span of one year. All variables of interest were extracted from electronic medical records. The situation may exacerbate the economic difficulties that already exist among cancer survivors, who may be suffering from both cancer related financial toxicity and economic pressures brought on by lost income and extended unemployment after the epidemic. Living in areas with scarce resources, like Southeast Asia, cancer survivors are likely to feel the effects of the pandemic more acutely. Patients may present with exacerbated diseases and at later stages of cancer, when treatment options tend to be more limited, as a result of delays and disruptions in timely access to cancer care. Patient having cancer lung are a susceptible, according to accumulating research. Latin America has little information on how the pandemic has affected medical care. Studies have been conducted to know the purpose of a robust healthcare facility for thoracic cancer, thyroid cancer patients with COVID-19 and the available resources to use. Middle age for the entire cohort (n=548) was 61.512.9 years. 23.9% of patients reported any modification in their course of treatment, of which 78.6% were brought on by the SARS-CoV-2. People having carcinomas patient populations most susceptible to the consequences of the Corona infection during the COVID-19 pandemic. The typical pneumonia is caused by an extracellular organism and alveolar exudates are present in air spaces. It is neutrophil in nature. It causes high grade fever and productive cough and pleurisy chest pain. X rays show large areas of consolidation.

Key words: Pandemic, Thyroid cancer, Pleuritic chest pain, Carcinomas

HOW TO CITE THIS ARTICLE: Adarsh Singharoy, Komal Muneshwar, Effect of COVID-19 in Cancer Patients, J Res Med Dent Sci, 2022, 10 (11): 200-204

Corresponding author: Dr. Komal Muneshwar E-mail: adarshroy6012@gmail.com Received: 29-Aug-2022, Manuscript No. JRMDS-22-71474; Editor assigned: 01-Sep-2022, PreQC No. JRMDS-22-71474 (PQ); Reviewed: 15-Sep-2022, QC No. JRMDS-22-71474; Revised: 31-Oct-2022, Manuscript No. JRMDS-22-71474 (R); Published: 08-Nov-2022

INTRODUCTION

The first case of the Corona virus was found in Wuhan after which the medical governing body of the world declared COVID 19 to be a pandemic [1]. The mortality of the virus seems to be quite in the low to midrange but the infectivity and morbidity is high enough and this makes the virus a potential threat for cancer patients. The most important factor for cancer patients other than morbidity is the financial burden they would face. In the on-going high treatment rates for cancer, a Corona infection would prove to be a double blow for these patients' finances. In the on-going lockdown the job losses and on-going inflation only add up to the cause. Fear among the cancer patients also arise when there are no special incentives or schemes from the government for such patients [2].

High blood pressure, circulatory strain blood pressure of greater than systolic 130 and diastolic of greater than 80,

is a basic changeable danger factor related with cardiovascular disease related with atherosclerosis [3]. The predominance of high blood pressure in United States grownups is close to half and greater rates interface plainly with progressing years. Accordingly 63% of grownups past 60 every years old hypertension case [4] a numerical that will keep on ascending as our all-inclusive community ages. Around half of US patients with high blood pressure are recommended angiotensin changing over stimulus in angiotensin converting enzyme and other antihypertensive enemies, aggregately called renin angiotensin system inhibitors and are in between the every now and again embraced antagonistic to hypertensive medications. Right off the bat reports from SARS-CoV-2 trouble places, that includes china and Italy and NYC. Saw greater velocities of high blood pressure in the midst of really truly, admitted SARS-CoV-2 patients. A gigantic United states assessment of five thousand seven hundred admitted cases showed a general high blood pressure speed of 56% [4] like high blood pressure rates bare essential from China11 and Italy9 (half and 49%, only). Regardless these experiences, the relationship among high blood pressure and SARS-CoV-2 is shady. Truth of Corona virus affliction is slanted in the inclination of more settled individuals who have a higher

commonness of high blood pressure [5]. The middle period of admitted cases in Italy and NYC. Was 63 years old and the rate with a high blood pressure affirmation is reliable with the rate found in everybody. While there is an over representation of high blood pressure among hospitalized and on a very basic level crippled Corona virus cases, it is sketchy if the relation is ordinary or based by age and other factors related with high blood pressure included by heartiness, DM, not set in stone kidney illness. In the southern parts of the Asian continent, the health and hospitals and the finances related to it are diversified, 20 lakh or higher number of new instances for carcinomas are identified each year [6], with an estimated 4 million people living with the disease during a five year period [7]. We had previously demonstrated through study that more than half of these patients belonged to the middle class and they have had to pay hefty sums of money many a times from loans frequently resulting in hardship and impoverishment [8]. Similar results were observed by analysis done per country.

LITERATURE REVIEW

Economic impact of COVID-19

Coming to the cancer patients who are old aged a majority of them would also have hypertension as comorbidity in it [9]. The principle drugs taken by these patients are either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker which has an effect on the renin angiotensin and aldosterone mechanism in the body. The principle organs affected in these patients cumulatively are the respiratory system, the cardiovascular system or the renal system. Various drugs administered for chemo or taken during the course of the Corona virus may cause substantial damage of their own to these organs and that can be catastrophic for these patients. Fever, coughing, shortness of breath and muscle soreness are typical signs of COVID-19. According to reports, 33% of COVID-19 patients experience serious consequences. The serious patient with systemic emergencies also needs special attention and care in the ICU. To be admitted to the intensive care unit. Due to their immunosuppressed state from having and receiving anticancer therapies like cancer chemotherapy or surgery, the carcinomas and sarcomas have more vulnerability serious Corona consequences. The extra representation of high blood pressure in between for the most part cleared out SARS-CoV-2 patients, there have been instances concerning the tremendous risk related to renin angiotensin receptor inhibition. Late conversations have analysed if angiotensin converting enzyme inhibitor and angiotensin receptor blocker verbalization [10,11] thusly working with SARS-CoV-2 affliction or adding to more veritable infection [12]. Findings from creature assessments have uncovered conflicting impacts of renin angiotensin inhibitors on level 2 and cellular improvement with little appearance regulation while others showing few changes of the late there is a shortfall of case information, in the cross section assessments of patients acquainted with

extended length renin angiotensin system treatments, plasma receptors action did not increase in treated subjects [13].

Considering worries in reference to the hypothetical danger of renin angiotensin system hindrance in SARS-CoV-2 cases, a few doctors have suggested ending of these hypertension drugs well informed authorities [14]. At this point, there is a negative assertion convincing affirmation that withdrawal of first line antihypertensive forestalls corrupting or consequences of the results clinically. Very large numbers of events of myocardium dead tissue, myocardial inflammation have been addressed in between SARS-CoV-2 cases and impedance of cardio protection cures, including RAA inhibitors, could incite no clinical compensation [14]. Patients who had undergone surgery or chemotherapy during the thirty days prior to who present with Corona virus than in people who had not [15]. Additionally, it was discovered that having a history of cancer increased the chance of serious consequences and was associated with worse COVID-19 results. Not ably, compared to individuals with other cancer types, people having carcinoma of lung have more likelihood of developing serious consequences [16]. Taking everything into account, a cross country study region of Mideast found that patients suffering from dangerous progression had a higher score chance of odd events than patients without the disease [9]. COVID pneumonia produced a 24percent fatality rate in sickness patients, compared to only 3% in non-cancer patients, according to one study [10]. Furthermore, these people are prone to viral shedding that never stops [11]. The secured structure is altered in a variety of ways in sick patients, exposing them to a higher danger of infection.

This could be due to specific dangerous improvement prescriptions, the severity of the disease, or the region where the fundamental infirmity starts [12]. Lympopenia successfully predicted the development of pneumonia in a few investigations of people with hematologic malignancies who also had respiratory viral infections [13-15]. Lympopenia has been found in the majority of COVID-19 patients who have been hospitalised, with nonsurvivors developing true lymphopenia over time [16-18]. Platelets are also crucial in the immune system and have antiviral effects against some infections [19]. Cancers like leukaemia and lymphoma, for example, attack and destroy normal bone marrow, resulting in thrombocytopenia and immuno compromisation. The formation of T cells, which aid in the elimination of viral infections, is required for a strong immune response to viral infections. According to another study of Corona patients, more than 70% of non-Intensive Suspected Unit (ICU) cases had decreased absolute T cells, but 95% of ICU patients had decreased inside and out T cells [20,21].

It is absolutely alright for the people with cancer to have the COVID-19 vaccine or as one may say we cannot emphasize enough on the need of these patients to have vaccine. There must be a mass drive and active campaign to focus on the emphasis of vaccination although people who have received the vaccine have less severe infections and reduced rates of hospitalization so people with cancer need to follow the safe precautions and value the need of the hours and need to maintain the sanctity strictly. If the person already has COVID-19, what should he do? The persons who had COVID in the past may believe that they have gathered immunity against the virus but sadly that is not the case here they need to be vaccinated also. The antibodies formed due to the infection would assist the antibodies formed from the vaccine which further enhances the immunity. Cancer patients if are re-infected with COVID-19 the vaccine ones have been known to show better treatment rates and less hospitalization. People who had got monoclonal antibodies for the treatment of COVID-19 must wait for an additional 90 days before getting the vaccine. Is a person with cancer eligible for additional doses if he or she has received the first dose of the vaccine? The answer to this question lies solely upon your radiologist or the oncologist. The oncologist should decide based on your parameters what is good for you. Are the vaccines safe for people with cancer? Yes although reports have suggested a small number of people develop allergic reactions to the vaccine in almost all of the cases it's mild and treats on itself. Only in a very few severely immune compromised patients from chemotherapy the reactions may exaggerate [22-26].

What if the person is in active treatment for cancer? Research is still going on what's the best time for patients with active treatment to get the vaccine if the person has a bone marrow or stem cell transplantation then the vaccine delivery needs to be delayed. It is also best for chemo patients to get the vaccine after the therapy is complete. The possible side effects of the vaccine are pain at the site of the injection, muscle sore, fever, cough etc.

Immunotherapy includes safe allotted spot inhibitors, T cell move treatment, vaccinations, and safe controlling drugs to treat unquestionable compromising improvement sorts [27]. There are no clear guidelines for continuing or initiating immunological treatment throughout the SARS-CoV-2 time frame. Regardless, a few possible side effects of this treatment could help you get where you want to go. Hyper activated T cell reaction with reactivity against standard tissue is the reason for these conceded results. Low platelet count and T cell mediated pneumonia move treatment, which unites disease entering white platelets and unusual receptor related T cell therapy, have astonishing inescapable after effects of immunity allotted spot limitation. TIL combination had discretionary effects that resulted in less number of WBCS can cause inflammatory mediators releasing antibodies have been linked to minor harm. Finally, certain safe switching experts can induce thrombocytopenia, sickness, leukopenia, and vascular weakness, which can lead to pleural radiation or pneumonic oedema. Surprisingly, some safe tinkering specialists who lower aggravation during corrupting have demonstrated restorative attestation in mice models smashed with various flu strains. In infirmity has been seen, with the highest levels of animosity and mortality (HSCT) [15,28,29]. The host safe system is discarded in favour of the provider's in the methodology for treating on an exceedingly important level. These patients are vulnerable to tainting for the first three months following relocation, with recovery to check partner taking up to a year in certain cases. According to the American Cancer Society (ACS) trusted source, it's the second most common cancer in both men and women. Lung cancer is a chronic, or long lasting, condition. Treatment goals can vary by the type and extent of the cancer, but typically focus on controlling its growth and spread. Where possible, treatment also seeks to eliminate the cancer. Corona is the sickness the causative factor being a respiratory virus. This virus is currently the cause of a pandemic that has sickened and killed millions of people worldwide. COVID-19 is generally an acute condition. This means that symptoms come on quickly and last a short time. While most people who become sick with COVID-19 have a mild or moderate illness, it can cause serious or critical illness in others. However, some people who have had COVID-19 experience lingering symptoms, such as fatigue and shortness of breath. These symptoms can last weeks or months after you first contract the virus. This is called long COVID. Cancer treatments can be hard on your body. As such, if you have lung cancer and contract COVID-19, you may need to defer some types of cancer treatment until you recover[30].

DISCUSSION

Doctors will make these types of treatment decisions on an individual basis. Your doctor will weigh the benefits and risks of continuing or deferring your cancer treatment while you have COVID-19. Some factors they'll consider include:

- The typicity and staging of your carcinoma
- Specific kind of modality of treating the cause being used or considered
- The risk of your cancer progressing
- Your level of lung function
- Your age and overall health.

In the initial CCC19 trial, 928 cancer patients who later received a COVID-19 diagnosis were examined for their results. Patients having a history of cancer were included, both those with active malignancy and those in remission. Both academic and community facilities around the United States provided care for them.

Targeted medications, endocrine therapy, radiation therapy and immunotherapy were other therapies. Doctors typically advise their cancer patients to get immunizations to guard against having Corona virus. But according to the findings of three additional trials, some cancer patients may not be as protected by the vaccine as those who do not have the condition. The results offer some of the first information on the COVID-19 vaccinations effectiveness in cancer patients, who were mainly left out of the early trials evaluating the vaccines. The studies were carried out by three independent organisations in France, the United Kingdom, and the United States. For many cancer survivors, chemotherapy is their last remaining option, but researchers in Seattle have just found a "totally unexpected" discovery that raises the possibility that the standard cancer treatment may actually be a double edged sword. Chemotherapy may potentially aid some malignancies in surviving, developing more quickly and developing resistance to treatment, if peter nelson and his associates at the Fred Hutchinson cancer research centre are correct. Chemotherapy is sometimes the only treatment left for cancer survivors, but recent study from Seattle area scientists raises the idea that chemotherapy may not be as effective as previously thought. If the chemo radiation treatment may perhaps help in the survival of carcinoma, grow more quickly, and develop a resistance to treatment. Scientists are learning more every day about Coronavirus sickness and how it affects people's daily lives in general. Severe Coronavirus illness is thought to be more likely in older adults and those who already have other medical disorders such heart disease, cancer, diabetes, hypertension, chronic lung disease, etc. Therefore, if you have one of the conditions listed above, it may cause dread or anxiety. However, if the person has a carcinoma and is a care giving individual if, do not worry. By according to the COVID-19 safety protocols, you may protect yourself and your loved ones from the deadly virus.

CONCLUSION

Corona patients who already are immunically and higher severity risk factor illness and mortality. The patient who haven't got infected and have carcinomas better immune system and lower risk of severe illness and mortality. The cancer types include haematological cancer, breast cancer, and lung cancer. Staging risk includes metastatic and stage 4 cancers of the various comorbidities include age, sex, race, smoking status, weak immune system, cancer severity; the economic burden of the cancer survivors is a cause of concern in developing countries. A strong health system is necessary to provide assistance to such patients. Chemo therapy and its adverse side effects also have to be taken in account while treating such patients. Given the circumstances and the condition of the healthcare system in the developing countries, hospitalization of these patients also possesses a grave danger as they are immuno compromised. Being a hypertensive or a diabetic can make matters worse. Proper planning and systematic sequestration of these patients have to be done in order to better these patients. The government and the private sector too need to work in collaboration to bring about the best results.

REFERENCES

- 1. WHO Coronavirus Disease (WHO). (COVID-19) Dashboard. Coronavirus disease (COVID-2019) situation reports, 2022.
- Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown ethology in Wuhan China: The mystery and the miracle. J Med Virol 2020; 92:401.

- 3. Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis 2020; 39:1011-1019.
- 4. WHO. Weekly epidemiological update on COVID-19 20 July 2021. 49th edition, 2021.
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209– 249.
- 6. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: A pilot study assessing out of pocket expenses and the insured cancer patient's experience. Oncologist 2013; 18:381–390.
- 7. Witte J, Mehlis K, Surmann B, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: A systematic review and its implications. Ann Oncol 2019; 30:1061-1070.
- 8. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping up action on the financial toxicity of cancer treatment. CA Cancer J Clin 2018; 68:153-165.
- 9. Chan RJ, Gordon LG, Tan CJ, et al. Relationships between financial toxicity and symptom burden in cancer survivors: A systematic review. J Pain Symptom Manage 2019; 57:646–660.
- 10. Weaver KE, Rowland JH, Bellizzi KM, et al. Forgoing medical care because of cost: Assessing disparities in healthcare access among cancer survivors living in the United States. Cancer 2010; 116:3493-3504.
- 11. Zafar SY, McNeil RB, Thomas CM, et al. Population based assessment of cancer survivors' financial burden and quality of life: A prospective cohort study. J Oncol Pract 2015; 11:145-150.
- 12. Baddour K, Kudrick L, Neopaney A, et al. Potential impact of the COVID-19 pandemic on financial toxicity in cancer survivors. Head Neck 2020; 42:1332-1338.
- 13. Sharp L, Carsin AE, Timmons A. Associations between cancers related financial stress and strain and psychological well-being among individuals living with cancer. Psychooncol 2013; 22:745–755.
- 14. Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors' quality of life. J Oncol Pract 2014; 10:332-338.
- 15. de Boer AG, Taskila T, Ojajarvi A, et al. Cancer survivors and unemployment: A meta-analysis and meta regression. JAMA 2009; 301:753-762.
- 16. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19 infected cancer patients: A journal of cancer research and clinical oncology 13 retrospective case study in three hospitals within Wuhan. China Ann Oncol 2020; 31:894-901.

- 17. Hollenberg MD, Epstein M. The innate immune response, microenvironment proteinases and the COVID-19 pandemic: Pathophysiologic mechanisms and emerging therapeutic targets. Kidney Int Suppl 2011; 2022:48–62.
- Matthews HK, Bertoli C, De Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol 2022; 23:74–88.
- 19. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382:970.
- 20. Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. J Infect 2020; 80:401-406.
- 21. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff 2013; 32:1143-1152.
- 22. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424.
- 23. Chongsuvivatwong V, Phua KH, Yap MT, et al. Health and health care systems in southeast Asia: Diversity and transitions. Lancet 2015; 377:429-437.
- 24. Kimman M, Jan S, Yip CH, et al. Catastrophic health expenditure and 12 month mortality associated

with cancer in Southeast Asia: Results from a longitudinal study in eight countries. BMC Med 2015; 13:190.

- 25. Action Study Group. Policy and priorities for national cancer control planning in low and middle income countries: lessons from the Association of Southeast Asian Nations (ASEAN) costs in oncology prospective cohort study. Eur J Cancer 2017; 74:26-37.
- 26. Hoang VM, Pham CP, Vu QM, et al. Household financial burden and poverty impacts of cancer treatment in Vietnam. Biomed Res Int 2017; 9350147.
- 27. Bhoo Pathy N, Ng CW, Lim GC, et al. Financial toxicity after cancer in a setting with universal health coverage: A call for urgent action. J Oncol Pract 2019; 15:e537-e546.
- 28. Ngelangel CA, Lam HY, Rivera AS, et al. Philippine Costs in Oncology (peso): Describing the economic impact of cancer on Filipino cancer patients using the ASEAN costs in oncology study dataset. Acta Medica Philippina 2018; 52:125-133.
- 29. Kong YC, Wong LP, Ng CW, et al. Understanding the financial needs following diagnosis of breast cancer in a setting with universal health coverage. Oncologist 2020; 25:497-504.
- 30. Tang KHD. Movement control as an effective measure against COVID-19 spread in Malaysia: An overview. J Public Health 2020; 13:1-4.